Breast cancer (invasive) · line 2 · Sacituzumab govitecan monotherapy (TNBC ≥2L; HR+/HER2- ≥3L)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	2
Track	standard
Linked regimen	`REG-SACITUZUMAB`

ID	`IND-BREAST-TNBC-2L-SACITUZUMAB`
Type	Indication
Status	reviewed 2026-04-27 \| pending_clinical_signoff
Diseases	`DIS-BREAST`
Sources	`SRC-ASCENT-BARDIA-2021` `SRC-ESMO-BREAST-METASTATIC-2024` `SRC-NCCN-BREAST-2025`

Notes

ESCAT IA. ASCENT established sacituzumab govitecan (anti-Trop-2 ADC with SN-38 payload) as standard ≥2L for metastatic TNBC pretreated with ≥2 prior chemo lines (≥1 in metastatic). No biomarker gating — Trop-2 expression is universal in TNBC. Severe AE profile: neutropenia G3+ 51% (G-CSF primary prophylaxis recommended), diarrhea G3+ 10%. UGT1A1*28 homozygous patients require dose reduction. Default 2L for non-BRCA TNBC; default 3L for BRCA-mut TNBC after PARPi failure. UA access barrier: not registered; named-patient import / EAP / cross-border only.

Used By

Algorithms

ALGO-BREAST-TNBC-2L - ALGO-BREAST-TNBC-2L